مجله دانشکده پزشکی اصفهان
پیاپی 597 (هفته اول دی 1399)

This study aimed to compare the hemodynamic effects of dexmedetomidine and midazolam in neurosurgery candidates who underwent skull-pin head-holder insertion.

In this randomized clinical trial study, 68 patients candidate for neurosurgery were divided into two groups receiving dexmedetomidine or midazolam. After induction of anesthesia, the patients received dexmedetomidine or midazolam based on the group they allocated to. Ten minutes after induction of anesthesia, the surgeon was allowed to insert the skull-pin head-holder. Hemodynamic variables were recorded before and during the surgery.

Among 68 studied patients, there was significant difference between the groups regarding systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.002), mean blood pressure (P = 0.450), and heart rate (P = 0.003). Systolic, diastolic, and mean blood pressure in the midazolam group was significantly higher at first, second, and third minute after the insertion of the skull-pin head-holder in comparison with the dexmedetomidine group. Moreover, the heart rate was significantly higher in the midazolam group before inserting the skull-pin head-holder up to 3 minutes after the insertion in comparison with the dexmedetomidine group (P < 0.050).

Compared with midazolam, dexmedetomidine showed a more significant effect on stabilizing hemodynamic parameters during craniotomies that required skull-pin head-holder insertion. Besides, the need for hemodynamic control drugs was lower after the administration of dexmedetomidine

This study aimed to investigate the relationship between Pender's Health Promotion Model constructs and applying nutritional supplements in patients with hypertension in rural areas of Isfahan Township, Iran.

In a cross-sectional study, 233 patients with high blood pressure were selected from rural health centers in Isfahan Township. Patient’s dietary intake was assessed by a 3-day dietary questionnaire, and cognitive factors and a commitment to nutritional approach with Pender Health Promotion Model. The relationship between dietary intake and nutritional approach was studied as well.

There was an inverse and significant relationship of 0.316 between sodium intake and knowledge (P < 0.001). Moreover, there was a significant negative correlation of 0.121 between the benefit score and the sodium intake (P = 0.002), but no relationship between other criteria (perceived self-efficacy, behavioral sensation, status affecting, and social support) and sodium intake.

The findings of this study showed that there was a significant relationship between Pender Health Promotion Model and nutritional approaches for controlling blood pressure. Therefore, it is recommended to use Pender Health Promotion Components in health units associated with hypertension.

Hepatotoxicity is a serious complication of anti-tuberculosis drugs, and so far, no ideal preventive measure has been suggested for it.. The aim of this study was determining the effects of Livercare tablet [combination of milk thistle, dandelion, barberry, turmeric (curcumin), and artichoke] in the prevention of hepatotoxicity induced by anti-tuberculosis drugs.

In a randomized controlled clinical trial study, 44 patients with pulmonary tuberculosis were divided into two groups of 22 patients. In the first group (intervention group), Livercare tablets made by HealthAid Company were prescribed twice a day for 2 weeks at the same time with the start of anti-tuberculosis drugs. In the second group (control group), only standard anti-tuberculosis treatment was prescribed. The incidence of hepatotoxicity was determined and compared between the two groups.

Examination of liver enzyme levels during two weeks from the start of anti-tuberculosis treatment showed that 7 patients (15.9%) had hepatotoxicity, of which 6 (27.3%) were in the control group and 1 (4.5%) in the intervention group. The incidence of hepatotoxicity was significantly lower in the intervention group (P = 0.039).

Concomitant use of the herbal drug Livecare seems to reduce the hepatotoxicity of anti-tuberculosis drugs significantly.